ABCB1 rs2032586: Understanding This Pharmacogenomic Variant

What each genotype means

What is rs2032586?

The rs2032586 variant is a single nucleotide polymorphism (SNP) found within the ABCB1 gene, also historically known as the MDR1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence. This specific variant is classified as a nonsynonymous change, meaning it results in an alteration of the amino acid sequence of the protein it encodes. Specifically, it is associated with the substitution of alanine for serine or threonine at position 893 in the P-glycoprotein structure. Because this protein is a critical component of cellular membranes, researchers have long investigated whether such structural changes affect the protein's ability to transport molecules across cell boundaries. It is one of several common variants in this gene that are frequently studied together as part of a haplotype, which is a set of DNA variations that tend to be inherited together.

The Role of the ABCB1 Gene

The ABCB1 gene encodes P-glycoprotein, an ATP-dependent efflux transporter found in the plasma membranes of many cell types throughout the body. Its primary function is to act as a biological gatekeeper, pumping various substances—including toxins, environmental pollutants, and many therapeutic drugs—out of cells. By doing so, P-glycoprotein helps protect sensitive tissues, such as the brain, the fetus, and the testes, from potentially harmful substances. It also plays a significant role in the absorption of drugs from the digestive tract and their subsequent elimination through the liver and kidneys. Because P-glycoprotein interacts with a wide array of structurally unrelated compounds, any genetic variation that alters its expression or kinetic activity has the potential to change how an individual absorbs, distributes, or clears specific medications, which is why it is a major focus of pharmacogenomic research.

Research and Clinical Evidence

Scientific research into rs2032586 has primarily focused on its potential to influence the pharmacokinetics of various drugs, such as digoxin, fexofenadine, and tacrolimus. While some studies have suggested that ABCB1 variants may contribute to inter-individual differences in drug response or the risk of adverse events, the overall evidence remains limited and sometimes inconsistent. Many published reviews note that the individual effect of any single ABCB1 polymorphism on P-glycoprotein activity appears to be relatively small. Furthermore, because these variants often exist in linkage disequilibrium—meaning they are inherited as a block—it is difficult to isolate the specific impact of rs2032586 from other nearby genetic changes. Consequently, while the variant is a well-characterized marker in pharmacogenomic studies, it is not currently used as a standalone clinical tool for routine drug dosing decisions. Further large-scale, diverse studies are required to clarify its clinical significance.

What This Means for You

If you have information about your rs2032586 genotype, it is important to understand that this data does not provide a definitive prediction of how you will respond to any specific medication. Pharmacogenomics is a complex field where genetic factors interact with clinical variables, such as age, weight, kidney function, and other medications you may be taking. Because the evidence linking this specific variant to clinical outcomes is limited, it should not be used to make independent decisions about your health or treatment. If you are concerned about how your genetics might influence your response to a prescribed drug, the most appropriate step is to discuss this with your physician or a clinical pharmacist. They can evaluate your entire clinical profile and determine if any adjustments to your treatment plan are necessary based on established clinical guidelines.

Frequently asked questions

Sources & further reading

Related variants in ABCB1